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Background: Desmoid-type fibromatosis is defined as an intermediate tumor that rarely occurs in the head and
neck of children. There is no doubt as to the value of complete surgical excision for desmoid-type fibromatosis.
However, in pediatric patients, surgeons may often be concerned about making a wide excision because of the
potential for functional morbidity. Some studies have reported a lack of correlation between margin status and
recurrence. Therefore, we discussed our findings with a focus on the state of surgical margins.
Case presentation: We report an unusual case of a 9-month-old Japanese girl who prior to presenting at our
hospital underwent debulking surgery twice with chemotherapy for desmoid-type fibromatosis of the tongue
at another hospital. We performed a partial glossectomy and simultaneous reconstruction with local flap and
achieved microscopic complete resection. We also reviewed available literature of pediatric desmoid-type fibromatosis
in the head and neck.
Conclusions: We described successful treatment for the refractory case of pediatric desmoid-type fibromatosis.
The review results showed that some microscopic incomplete resections of tumors in pediatric patients with
desmoid-type fibromatosis tended to be acceptable with surgical treatment.
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According to the World Health Organization’s classifica-
tion of head and neck tumors [1], desmoid-type fibro-
matosis (DF) is defined as a borderline tumor of soft
tissues that has low malignant potential. DF is character-
ized by local aggressiveness with an approximate 20 %
local recurrence rate, but without metastasis [1]. The an-
nual incidence of DF is presumed to be 0.2 to 0.4 per
100,000 individuals [2]. Among cases of DF, 7 to 15 % of
tumors occur in the head and neck [1, 3, 4]. A paper on
the European Organisation for Research and Treatment
of Cancer (EORTC)/Soft Tissue and Bone Sarcoma
Group’s position on DF reported that a “watch and wait
strategy” is the first choice in the treatment of DF in all* Correspondence: kawana@keio.jp
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should be considered to be a treatment option if postop-
erative morbidity is acceptable [5]. Although complete
resection (negative microscopic margin; CR) of the
tumor is thought to be the reference standard for suc-
cessful treatment in patients with DF uncontrolled by
other treatment approaches, resection in the head and
neck region is often difficult because of the presence of
vital structures [6]. This problem is worse in pediatric
patients. In pediatric patients with DF uncontrolled by
non-surgical treatments, surgeons sometimes are con-
cerned about performing wide resections because of the
high potential of postoperative morbidity. When a large
tumor exists close to a vital structure, surgery with an
adequate safety margin may be challenging. Although
some successful cases with incomplete resection or with-
out surgery have been reported [7–12], a randomized
trial of treatment strategies has not yet been reported.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The patient could not close her mouth completely because
of the presence of a part of the tumor outside her mouth. The
maximum tumor size reached 5 cm
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how to decide on performing ablation in pediatric patients
with DF. Thus, we reviewed the available literature to de-
termine various factors that could influence treatment de-
cisions in pediatric DF. In particular, we focused on the
correlation between margin status and disease condition
and if there are differences in disease condition between
microscopic incomplete resection (microscopic positive
margin but no remaining gross tumor; MIR) and gross in-
complete resection. As part of our study, we included a
case involving a 9-month-old Japanese girl with DF of theFig. 2 a Magnetic resonance imaging (MRI) showing huge mass with cont
show the posibility of infiltration into the root of the tongue. Arrows indicatongue who was surgically treated at our oral and maxillo-
facial surgery division.
Case presentation
A 9-month-old Japanese girl was referred to our hospital
because of a growing tumor on her tongue. Her family
noted the mass in her tongue at the age of 3 months. She
twice underwent debulking surgery with medical treat-
ment, involving NSAIDs, vinblastine plus methotrexate,
and vinblastine plus actinomycin-d at another hospital.
The analysis of a resected specimen led to the diagnosis of
DF at the age of 7 months. However, the tumor was not
controlled. When she was brought to our hospital, the
tumor rapidly increased, and a portion popped out of her
mouth (Fig. 1). She could not close her mouth completely,
but swallowing dysfunction and upper respiratory infection
was not observed. Her swallowing function was comple-
mented by trick motion of the unaffected side. She had no
history of any disorders associated with DF. A whole body
computed tomography examination revealed no signs of
any other tumoral lesions. On the basis of radiological ex-
aminations and the clinical course, we made the decision
to perform radical surgery. Magnetic resonance imaging
(MRI) with contrast enhancement showed the mass (Fig. 2).
A partial glossectomy with a 5-mm safety margin and sim-
ultaneous reconstruction with a local flap were performed
under general anesthesia (Fig. 3). After excision, primary
wound closure was performed without any graft while be-
ing careful to preserve postoperative function. We con-
firmed a microscopic CR in a pathological examination of
the surgical specimen. Her postoperative progress was ex-
tremely good, and no functional morbidity, such as eating
dysfunction or dysphonia, was observed. She had no indi-
cation of recurrence after a year (Fig. 4).
Discussion
We performed a review of the literature by searching
PubMed and using the keywords “desmoid,” “fibromatosis,”rast enhancement in the right side. b MRI of saggital plane did not
te the areas of tumor with contrast enhancement
Fig. 3 a A partial glossectomy with a 5-mm safety margin was performed. b We performed simultaneous reconstruction with a local flap and
rotation of the anterior tongue on the unaffected side into the tongue defect on the affected side
Table 1 Primary tumor sites
Location of tumors The number of patients
Mandible 35 (2)
Submandibular area 22 (2)
Neck 13 (5)
Tongue 12 (3)
Cervical paraspinal area 8 (7)
Infratemporal fossa 8 (3)
Parapharyngeal space 7 (1)
Maxilla 7 (2)
Peritracheal area 3 (3)
Paranasal sinus (ethmoidal, sphenoid) 3 (1)
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when we searched cross-sectionally. The established exclu-
sion criteria were as follows: details in individual cases not
described, patients who were >19-years old, reports not
written in English, and tumor sites not in the head and
neck. We examined the following factors in all cases: age,
sex, tumor site, tumor size, treatment, margin status, recur-
rence, complication, disease condition, and follow-up dur-
ation. The descriptive terms of incomplete resection (MIR),
residual tumor, positive, and CR, which relate to margin
status, were defined as follows: MIR, microscopic positive
margin but no remaining gross tumor; residual tumor,
remaining gross tumor; positive, positive resection margin,
but we could not determine if it was MIR or a residual
tumor; CR, negative microscopic margin; and NR, data not
shown. The cases were reviewed in detail and are discussed
in this case report.
We identified 141 patients with DF in the head and
neck [7, 8, 13–72]. Age at diagnosis ranged from birth to
18 years, and the mean age was 4 years 3 months. The
sex of the patient was reported in 92 % of all cases (67
males and 63 females). Regarding the tumor sites, a ma-
jority of tumors arose from the mandible (25 %). OtherFig. 4 Intraoral findings after a year postoperatively












The numbers within parentheses are the numbers of recurrences in patients
with surgery
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fossa, neck, peritracheal area, and paraspinal area. A list
of tumor sites is presented in Table 1. We were able to
identify the tumor size in 78 (55 %) patients. The aver-
age tumor size was 43.6 mm (range, 5 to 100 mm). Sur-
gery was performed in 125 (88.6 %) patients during the
treatment period, and the remaining patients were
treated only with chemotherapy (12 patients), the
watch and wait strategy (3 patients), or a combination
of radiation and chemotherapy (1 patient). Margin
status was identified in 78 (62.4 %) of the 125 pa-
tients. The number of patients who had MIR, residual
tumors, positive status, and CRs was 24, 19, 19, and
16, respectively. Recurrence was observed in 34
(27.2 %) of the 125 patients with surgery. The most
common margin status was residual, which was ob-
served in 14 patients. The number of patients who
had positive status, MIR, CR, and NR was 7, 8, 1,
and 4, respectively (Fig. 5). Postoperative complica-
tions were identified in detail in 13 patients. Trismus
was the most common complication (n=6). Two pa-
tients experienced secondary papillary carcinoma due
to radiation therapy. Osteomyelitis (n=2), slight ptosis
due to a sectioned facial nerve (n=1), restrictive neck
movement (n=1), and Claude–Bernard–Horner syn-
drome (n=1) were confirmed. The disease condition
was identified in 126 of the 140 patients (Fig. 6). De-
tails were not reported for 15 patients. Ninety-seven
patients showed no evidence of disease (NED). Stable
disease (SD), partial response (PR), progressive disease
(PD), and death occurred in 15, 6, 5, and 3 patients,
respectively. The average follow-up duration was
53.3 months (range, 2 to 298 months).
The most common tumor site in the recurrent pa-
tients was the cervical paraspinal region (seven pa-
tients). The next most common tumor site was theFig. 5 Details of margin status and disease condition in recurrent patients.
incomplete resection, NED no evidence of disease, NR no report, PD progre
gross incomplete resection, SD stable diseaseneck (five patients). Other sites we could identify
were as follows: peritracheal area, infratemporal
fossa, submandibular area, and tongue. All tumor
sites in the recurrent patients are shown in Table 1.
The recurrence rates for each margin status were
MIR, 7 (29.1 %) of 24; residual, 14 (73.6 %) of 19;
positive, 8 (42.1 %) of 19; and CR, 1 (6.2 %) of 16
patients (Fig. 7). There were 29 patients with positive
margins without recurrence; “positive” status as used
here includes MIR, residual, and positive status. Ad-
juvant therapies for these patients were as follows. In
the case of MIR without recurrence (n=15), observa-
tion (n=9), chemotherapy (n=4), and radiation (n=2)
were performed. In the case of residual tumors with-
out recurrence (n=4), all patients spontaneously
regressed. In positive patients without recurrence
(n=10), observation (n=3), only chemotherapy (n=5),
and administration of NSAIDs plus chemotherapy
(n=2) were performed.
In recurrent patients, the relationship between margin
status (n=31) and disease condition was confirmed as
follows (Fig. 8). In the case of MIR (n=7), six (85.7 %) of
seven patients had NED because second surgeries had
been performed. One of the seven patients with SD was
treated only with chemotherapy. In the case of residual
tumors (n=14), there were two patients with NED, seven
with SD, two with PR, two with PD, and one who died.
Only 14.2 % of the patients showed controlled NED. In
the case of positive status (n=9), there were two patients
with NED, five with SD, one with PD, and one who died.
There was NED in 11.1 % of the patients. The patient
having CR with recurrence (n=1) had controlled NED.
The patients having MIR (85.7 %) and CR (100 %) with
recurrence had high rates of NED. It is notable that all
recurrent patients with controlled NED were rescued by
second surgery.CR complete resection, DOD dead of disease, MIR microscopic
ssive disease, Positive MIR or Residual, PR partial response, Residual
Fig. 6 Disease condition in all patients (n=141). DOD dead of
disease, NED no evidence of disease, NR no report, PD
progressive disease, PR partial response, SD stable disease
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all recurrent patients (n=34) with surgery was 14 with
NED, 13 with SD, 2 with PR, 3 with PD, and 2 who died
(Fig. 5). Of all recurrent patients with surgery, 41.1 %
had controlled NED. Consequently, in all cases in which
surgery was performed, 91 (72.8 %) patients had con-
trolled NED. The mean follow-up duration for patients
with surgery was 53.3 months. The result of our litera-
ture review was summarized in Table 2.
The main finding of our study was that the tumor
control rate tended to be high in cases of MIR. More-
over, there were 29 margin-positive patients who were
without recurrence. A majority of these patients had
MIR (n=15), and 15 (62.5 %) of 24 patients with MIRFig. 7 The number of recurrences for each margin status. CR complete res
microscopic incomplete resection or residual gross incomplete resection, Rdid not show recurrence. In our view, these results sug-
gest that a finding of MIR could be acceptable during
local aggressive DF treatment in children. A paper on
EORTC’s position on DF in all populations [5] proposed
that if positive microscopic surgical margins were found
at a pathological examination, no further treatment
should be considered. Our review results supported this
position in pediatric patients with head and neck DF.
Wide resection may induce long-term functional mor-
bidity, especially in children, and may require recon-
struction. Even though microvascular reconstruction is
useful in pediatric patients for well-experienced surgeons
[73, 74], the decision to proceed with wide resection
should be carefully considered; the results of this study
may be useful when making decisions in such cases.
If progression occurs after the watch and wait strategy
has been pursued, medical therapy is clearly recom-
mended in patients with head and neck DF according to
the paper on EORTC’s position [5]. However, a standard
treatment is yet to be established. Previous prospective
studies in pediatric patients with DF, including a phase
II trial of vinblastine plus methotrexate and tamoxifen
plus NSAIDs, have reported that the CR and PR rates
were 19.2 % and 8 %, respectively [75, 76]. Even when
CRs are included, the total response rate is insufficient.
The restrictive effectiveness of chemotherapy regimens,
such as liposomal doxorubicin, anthracycline-based
regimen, imatinib, and sorafenib, in the total population
has been confirmed [77–80]. However, no high-grade
evidence study (that is, a randomized phase III trial)
has been reported. In the present study, in only one
patient, chemotherapy using Adriamycin (doxorubicin)ection, MIR microscopic incomplete resection, NR no report, Positive
esidual gross incomplete resection
Fig. 8 Relationship between margin status and disease condition in the recurrent patients. CR complete resection, DOD dead of disease,
MIR microscopic incomplete resection, NED no evidence of disease, PD progressive disease, Positive microscopic incomplete resection or
residual gross incomplete resection, PR partial response, Residual gross incomplete resection, SD stable disease
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current patients, there were none with controlled
NED who had been treated only with subsequent
chemotherapy. They were rescued by second surgery.
Therefore, at present, the therapeutic effect of chemo-
therapy may be limited in pediatric DF treatment. A
randomized trial would be needed to confirm the effi-
cacy of chemotherapy in pediatric DF treatment.Table 2 The results of literature review
Summary of literature review
The number of patients 141








Recurrence rate (%) in patients with surgery 27.2
Average follow-up duration (months) 53.3
Abstraction of principal information
1. In the margin positive patients (N=62), 29 patients did not show
recurrence. After initial surgery, 16 of them did not need additional
treatment.
2. In the patients having MIR, the recurrence rate (29.1 %) is lower and
the NED rate (85.7 %) is higher than other margin positive status.
3. In the recurrent patients who had NED, all of them were treated with
second surgery.
4. We identified postoperative complications in detail in 13 patients
including radiation-induced secondary papillary carcinoma.
MIR microscopic incomplete resection, NED no evidence of disease, NR
no reportAlthough previous reports have indicated that treat-
ments with surgery and radiotherapy in all populations
improve the progression-free survival rate relative to
that of surgery alone [3, 81], the use of radiotherapy dur-
ing DF treatment is controversial. However, in pediatric
patients, radiotherapy may be less available because of
late adverse effects and lower effectiveness. Side effects
including secondary carcinoma related to radiotherapy
for DF in pediatric and young-adult patients have been
reported [53, 82]. A medium-sized retrospective study
involving 30 patients in a single institution who were
treated with radiotherapy for pediatric and young-adult
DF reported a lower regional control rate for patients
who were <18-years old (20 %) than for those who were
18 to 30-years old (63 %) [53]. In the present study, 13
patients received radiotherapy, and complications were
identified in three patients: two patients developed sec-
ondary papillary thyroid cancer after total doses of
55 Gy and 50 to 60 Gy (not specified), and one devel-
oped osteoradionecrosis after a total dose of 55 Gy.
There is no clearly standardized evidence-based radi-
ation strategy for pediatric head and neck DF. Some
refractory patients may need radiation therapy. How-
ever, it may not be reasonable to routinely consider
radiotherapy for pediatric patients with DF having
positive margins.
Conclusions
The present study cannot provide the same level of evi-
dence as could be obtained in a prospective study, and
no single institution retrospective studies were included
in the review because details were lacking. However, we
believe that the collected results can be helpful in
making treatment decisions, especially those involving
Miyashita et al. Journal of Medical Case Reports  (2016) 10:173 Page 7 of 8surgery, in pediatric patients with DF. In summary,
microscopic positive margins in pediatric DF did not
always lead to an uncontrolled condition. In some
patients, such findings appeared to be acceptable in
pediatric patients with local aggressive DF. Nevertheless,
further evidence-based approaches are needed before DF
treatment strategies can be standardized.
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